CROWD-COMPARE
Cluster and Registry Trial of the Working Group of Heart Failure in Denmark. Are Carvedilol and Metoprolol Succinate Comparable Treatments in Heart Failure Patients With Reduced Ejection Fraction
Sponsor study identifier
observational
5,600
1 country
1
Study Start
January 3, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
January 2, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 18, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The objective of CROWD-COMPARE is to compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 18, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 29, 2021
Actual (reported)August 9, 2021
Actual (reported)January 3, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 2, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 18, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
A combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.
To compare the efficacy of carvedilol and metoprolol succinate in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
Four years with randomized cluster allocation and two year of follow-up.
All-cause mortality.
Four years with randomized cluster allocation and two year of follow-up.
A combined endpoint of all-cause mortality and first hospitalization for worsening heart failure according to heart rhythm (sinus rhythm or atrial fibrillation/flutter).
Four years with randomized cluster allocation and two year of follow-up.
Cost-effectiveness analysis of each strategy.
Four years with randomized cluster allocation and two year of follow-up.
Proportion of patients who remained on beta-blocker treatment for a minimum of one year.
Four years with randomized cluster allocation and two year of follow-up.
Proportion of patients who switched from their initially prescribed beta-blocker to the other.
Four years with randomized cluster allocation and two year of follow-up.
Treated with Carvedilol
Treated with Metoprolol succinate
To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
To compare the efficacy of carvedilol and metoprolol succinate on all-cause mortality or first hospitalization for worsening heart failure in patients with heart failure with reduced ejection fraction with an indication for treatment with beta-blockers.
All 23 danish departments of cardiology with a heart failure clinic associated, which report to the Danish Heart Failure Registry are eligible.
Department of Cardiology, Odense University Hospital
Odense, Region Syddanmark, 5000, Denmark
First Submitted
July 29, 2021
First Posted
August 9, 2021
Study Start
January 3, 2022
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
Usability and Feasibility of a Personalized, Web-based Education and Self-management Approach for Patients With Chronic Heart Failure Across Four European Sites
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
January 2, 2028
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 18, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 16, 2021
Record last verified: 2021-08
Final results.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: